Chapter 8
A regenerative-medicine product is living material that changes while it is being made. A vial of induced pluripotent cells at passage 15 is not the same object as the same line at passage 5. A scaffold that degrades faster than the tissue grows has failed, even if it passed every bench test on the day it was manufactured. WIA-BIO-020 is therefore written less as a catalogue of facts than as a set of records and checks that follow a preparation from its biological source to a patient outcome. This chapter shows how those records are assembled into a working system, how that system exposes its data, and how it is judged against the quality and regulatory gates that surround cell and tissue therapies.
The standard's own scope statement lists six areas: stem cell types, culture and differentiation; regeneration mechanisms; scaffold design and biomaterials; growth factor delivery; clinical applications and protocols; and regulatory compliance (FDA RMAT, EMA ATMP). An implementation has to be able to speak about all six, because a failure in one usually surfaces in another. Poor growth-factor stability shows up as low marker expression, and a scaffold that cannot be vascularised shows up as a poor integration score.
The specification states that any compliant system must include six components. Each one answers a specific failure mode of the field.
| Component | What the standard requires | Where it surfaces in practice |
|---|---|---|
| Cell Source Management | Track origin, passage, characterization | Preparation records, cell characterization envelope |
| Differentiation Protocols | Standardized, validated methods | Differentiation efficiency target above 80% for clinical applications |
| Quality Control | Real-time monitoring and testing | QC result submissions, cleanroom telemetry |
| Growth Factor Calculator | Optimize dosing and timing | Factor registry, release-kinetics models |
| Scaffold Designer | Material, porosity, mechanics optimization | Scaffold design request and response |
| Clinical Tracker | Patient outcomes and safety monitoring | Clinical application records, adverse-event log |
Cell Source Management comes first because every later judgement depends on knowing what the cells are. The standard defines identity differently for each of the four stem cell families it classifies, and a system must encode those differences rather than apply one generic marker panel.
| Cell type | Source | Identity and quality criteria in the standard |
|---|---|---|
| Embryonic (ESC) | Inner cell mass of a day 5-6 blastocyst | OCT4, SOX2, NANOG expression; OCT4⁺, NANOG⁺, SSEA-4⁺ in culture; passage every 3-5 days at 70-80% confluence |
| Induced pluripotent (iPSC) | Reprogrammed fibroblasts or blood cells (OCT4, SOX2, KLF4, c-MYC) | Normal 46-chromosome karyotype; pluripotency marker expression above 90%; teratoma assay; three-germ-layer potential; epigenetic reprogramming verification |
| Mesenchymal (MSC) | Bone marrow, adipose tissue, umbilical cord, dental pulp | ISCT 2006 criteria: plastic adherence; CD73, CD90, CD105 positive (above 95%); CD45, CD34, CD14, CD19, HLA-DR negative (below 2%); tri-lineage differentiation |
| Hematopoietic (HSC) | Bone marrow, peripheral blood, cord blood | CD34⁺, CD133⁺, CD90⁺; lineage markers negative |
Two practical consequences follow. First, an iPSC preparation and an MSC preparation cannot share one acceptance rule. The first is accepted on high expression of pluripotency markers and a normal karyotype, the second on a positive-and-negative panel plus functional differentiation. Second, the standard's MSC immunomodulatory properties (IL-10, TGF-β and PGE2 secretion, T-cell suppression, M1 to M2 macrophage polarization, low HLA class I and no HLA class II) are the reason MSCs are candidates for allogeneic use. A system that records only the cell type, and not the immunological profile, loses the information needed to assess the rejection risk that error code B006 later flags.
The Phase 2 interface defines a small, resource-oriented surface. Its endpoints correspond directly to the six components above.
POST /regenerative-medicine/v1/preparations # register cell preparation
GET /regenerative-medicine/v1/preparations/{id} # fetch preparation record
POST /regenerative-medicine/v1/factors # register growth factor
POST /regenerative-medicine/v1/applications # register clinical application
GET /regenerative-medicine/v1/audit/{prepId} # audit trail
POST /regenerative-medicine/v1/qc-results # contribute QC measurement
GET /regenerative-medicine/v1/safety/incidents # adverse-event log
WS /regenerative-medicine/v1/cleanroom/stream # cleanroom telemetryEvery endpoint follows the discovery convention at /.well-known/wia-regenerative-medicine. Registering a preparation returns a stable prepId, and the audit endpoint is keyed on that identifier. The identifier is how a patient outcome months later can be traced back to the exact culture, passage and growth-factor lot that produced the graft.
Alongside the resource endpoints, the standard specifies three calculation interfaces written as TypeScript types. They are shown here in abbreviated form.
interface RegenerationRequest {
tissueType: 'cardiac' | 'neural' | 'bone' | 'cartilage' | 'skin';
cellDensity: number; // cells/ml
timeFrame: number; // days
growthFactors: string[];
}
interface RegenerationResponse {
rate: number; // cells/day
recoveryPercentage: number;
timeToComplete: number; // days
feasibility: 'high' | 'medium' | 'low';
}
interface SurvivalResponse {
survivalRate: number; // 0-100%
viability: 'excellent' | 'good' | 'fair' | 'poor';
recommendations: string[];
}
interface ScaffoldRequest {
tissueType: string;
material: string;
porosity: number; // 0-1
size: number; // cm³
mechanicalRequirements: { youngModulus?: number; compressiveStrength?: number };
}The units in these types are the most common source of integration mistakes. Scaffold porosity is a fraction between 0 and 1 in the request, while the design-principles section of the standard states the target as 70-90%. Survival is reported on a 0-100% scale, while the characterization record in the next example stores viability as a fraction (0.89). The pore size in the scaffold response is in micrometres, degradation time is in months, and cell density is per millilitre. An adapter layer should convert once, at the boundary, and never inside the calculation code.
The interface fixes inputs and outputs, not the solver behind them. The mechanistic vocabulary comes from Section 3 of the specification. Tissue volume follows dT/dt = α × C × G − β × T, where C is cell density, G is growth-factor concentration, α is a regeneration coefficient and β a degradation coefficient. Integration is scored as I = (V_integrated / V_total) × F_vascular × F_mechanical, with a target of at least 0.8. Because the integration score is a product, a graft that is well vascularised but mechanically mismatched is penalised just as heavily as the reverse.
The two canonical record formats in the standard are the cell characterization record and the tissue regeneration record:
{
"cellType": "iPSC",
"passage": 15,
"markers": { "OCT4": 0.95, "NANOG": 0.92, "SSEA4": 0.94 },
"viability": 0.89,
"karyotype": "46,XY",
"mycoplasma": "negative",
"doubling_time_hours": 24
}{
"tissue": "cardiac",
"patient_id": "P12345",
"baseline": { "ejection_fraction": 0.35, "infarct_size_cm2": 15 },
"post_treatment": { "ejection_fraction": 0.42, "infarct_size_cm2": 10, "vessel_density": 320 },
"improvement_percentage": 20
}Read against the standard's thresholds, the first record is a passing iPSC preparation. All three markers exceed 90%, viability exceeds 70%, the karyotype is normal and mycoplasma is negative. In the second record, the vessel density of 320 sits inside the 200-400 vessels/mm² range given for healthy tissue. The reported 20% matches the relative change in ejection fraction (0.35 to 0.42), though the material does not define the field, so an implementer should document how improvement_percentage is computed rather than assume it.
The standard publishes no market-size figures, and none are invented here. What the specification does show is where adoption pressure comes from. Programmes that submit to a regulator need a CMC section, nonclinical toxicology and biodistribution data, and trial protocols. The RMAT route requires pre-IND meeting documentation, and the EMA route requires a risk management plan and a pharmacovigilance system. Each of these is a document assembled from records, and organisations that already keep their cell source, QC and outcome data in a consistent structure assemble them with less rework.
The prospective users are those who register preparations, record clinical applications and read back audit trails. They include cell-processing facilities, groups running clinical programmes, and sponsors preparing submissions. A shared format matters most at the hand-offs between these parties. A cell line characterized at one site and expanded at another is only useful if the passage history and QC results travel with it in a form both sides read the same way.
The tissueType enumeration (cardiac, neural, bone, cartilage, skin) is a short list, but each value implies a different combination of cells, factors and scaffold. The standard supplies enough parameters to show how the combinations differ.
| Tissue | Growth factors named in the standard | Scaffold and mechanical targets |
|---|---|---|
| Bone | BMP-2 (bone formation, 50-200 ng/ml, osteoblasts) | Pores of 100-500 μm; Young's modulus 10-20 GPa; RUNX2 as the osteogenic commitment factor |
| Cartilage | TGF-β (ECM production, 1-10 ng/ml) | Pores of 50-150 μm; modulus 0.5-2 MPa; chitosan and hyaluronic acid among the natural materials |
| Skin | EGF (keratinocytes, 5-50 ng/ml); PDGF (fibroblasts, 10-100 ng/ml) | Modulus 0.1-1 MPa; collagen, gelatin and fibrin among the natural materials |
| Neural | BDNF (10-100 ng/ml); NGF (50-200 ng/ml) | Neurogenic MSC potential is described as limited |
| Cardiac | VEGF (angiogenesis, 10-50 ng/ml) | Outcome measured as ejection fraction, infarct size and vessel density |
Delivery is the other axis. A bolus injection is simple and immediate, but follows C(t) = C₀ × e^(−kt) with growth-factor half-lives of 2-24 hours. The comprehensive factor table makes the problem concrete: TGF-β1 lasts 2-3 minutes, BMP-2 about 7 minutes, and BDNF 1-10 minutes, while IGF-1 lasts 12-15 hours. For short-lived factors, scaffold-based delivery, where release follows M_released(t) = M_total × (1 − e^(−kt)), or microsphere encapsulation (1-200 μm, released by diffusion, polymer degradation or osmotic pressure) is the standard's answer. The same table records storage conditions (−80°C for VEGF-A, TGF-β1 and BDNF; −20°C for FGF-2, BMP-2, IGF-1 and EGF), which a growth-factor registry should keep next to the dose.
Scaffold choice is bound to timing in the same way. PLGA degrades over 1-12 months, PLA over 12-24 months and PCL over 24-36 months, while alginate degrades non-enzymatically. Error code B004, "scaffold degradation too fast", exists because the match between degradation and tissue growth cannot be checked from the material alone. It needs the regeneration-rate estimate that the RegenerationResponse provides.
Vascularization is the recurring bottleneck across tissues. The standard's sprouting model has tip cells following a VEGF gradient, stalk cells forming the lumen, and pericytes stabilising the vessel. VEGF binding VEGFR2 activates ERK1/2 and Akt to drive endothelial proliferation. Vessel density, measured in vessels per mm², is therefore recorded in the cardiac outcome example, and the homing axes (SDF-1/CXCR4, VEGF, selectins and integrins) appear in the migration section as the signals a delivery strategy tries to reinforce.
The regulatory section maps the system's data onto two pathways. The FDA RMAT designation applies to a cell or gene therapy intended to treat, modify or cure a serious condition and supported by preliminary clinical evidence. It opens access to Fast Track, Breakthrough Therapy, Priority Review and Accelerated Approval. The EMA ATMP framework sorts products into gene therapy, somatic cell therapy, tissue-engineered and combined products, and asks for GMP quality, preclinical safety, clinical efficacy, a risk management plan and pharmacovigilance. The integration phase of the standard also names USP, ISO 14644, 21 CFR 1271, ICH and GMP Annex 1 as the surrounding ecosystem.
The lot-release test table is where the data formats and the regulations meet:
| Test | Acceptance criterion |
|---|---|
| Sterility | No growth over 14 days |
| Endotoxin | <5 EU/kg body weight |
| Mycoplasma | Negative |
| Viability | >70% |
| Identity | Marker expression >90% |
| Purity | Contaminating cells <5% |
| Potency | Functional assay specific to the product |
| Karyotype | Normal, if applicable |
Manufacturing environment parameters sit beside these: an ISO Class 5 (Class 100) clean room with fewer than 3,520 particles of 0.5 μm or larger per cubic metre, 20-24°C, 30-60% relative humidity, and sterility results below 1 CFU per sample. This is the logic behind the cleanroom telemetry stream. Particle counts, temperature and humidity are continuous measurements, and a stream attached to the preparation record lets a batch be judged against the conditions it was actually made under. The documentation expected alongside includes Master Cell Bank characterization, batch production records, QC results and chain-of-custody records.
The standard's error codes turn these criteria into machine-readable outcomes:
| Code | Meaning | Prescribed action |
|---|---|---|
| B001 | Cell contamination detected | Discard culture, decontaminate |
| B002 | Low viability (<70%) | Optimize culture conditions |
| B003 | Marker expression insufficient | Extend culture, retest |
| B004 | Scaffold degradation too fast | Change material or crosslinking |
| B005 | Growth factor instability | Add stabilizers, reduce temperature |
| B006 | Immune rejection risk | HLA matching, immunosuppression |
A gate that applies these thresholds to a characterization record is short enough to show. This is an illustration of how an implementer might connect the record fields to the codes, not text from the standard. Mapping a positive mycoplasma result to B001 is an implementation choice, since the standard lists the code without tying it to a specific test.
function releaseGate(rec: {
viability: number; markers: Record<string, number>; mycoplasma: string;
}): string[] {
const codes: string[] = [];
if (rec.mycoplasma !== 'negative') codes.push('B001');
if (rec.viability < 0.70) codes.push('B002');
if (Object.values(rec.markers).some(v => v <= 0.90)) codes.push('B003');
return codes; // empty array: no gate failures
}One caution applies. The standard sets viability at 70% in both the release table and B002, but sets the identity expectation at 90% and the MSC positive-marker threshold at 95%. A system that collapses these into one "marker threshold" setting will either reject valid MSC lots or accept weak iPSC lots, so the thresholds should be configured per cell type.
Most of the work in an implementation lies in the plumbing around the biology. Preparation records and patient-linked outcome records are sensitive, and the shared companion specifications call for AES-256 at rest, TLS 1.3 in transit, role-based access with multi-factor authentication, and comprehensive audit logging. The audit trail also serves a clinical purpose: when an adverse event appears in the safety log, the trail is what connects it back to a specific preparation. Beyond that, the cell-therapy-specific risks deserve more attention than the generic engineering ones.
η = (N_iPSC / N_initial) × 100%, with typical values of 0.01% to 3% depending on method. Differentiation efficiency (D_eff) is held to above 80% for clinical applications. Store numerator and denominator, not just the percentage, so a result can be recalculated.The specification is at version 1.0.0 and says little about its own evolution, so the points below are observations about open edges in the document and not roadmap claims. The reference list points to companion standards for cell culture technology (WIA-BIO-002), tissue engineering (WIA-BIO-005), patient health monitoring (WIA-HEALTH) and a universal biomedical API (WIA-OMNI-API). The clinical tracker is the component most likely to depend on those neighbours, since outcome measures such as ejection fraction already come from monitoring systems outside the cell-processing facility.
Several parts of the text are described by ranges and are likely candidates for refinement as evidence accumulates. These include the printing parameters for bioprinting (50-200 μm resolution, above 85% post-print viability), the electrospinning and freeze-drying settings, and the optimal dose ranges for growth factors. A real deployment should treat them as configurable defaults with the source recorded, not hard-coded constants. The cleanroom stream and adverse-event log also point toward the continuous monitoring that regulators increasingly expect, but the material defines only their endpoints. The record schemas for them are for implementers to specify.
Certifying a WIA-BIO-020 implementation comes down to demonstrating that the six required components work together on real preparations. Cell sources are identified by type-specific criteria (pluripotency markers and karyotype for iPSCs, the ISCT 2006 panel for MSCs). Calculation and registry endpoints share one set of units. Characterization and outcome records are written in the standard's JSON shapes. Every lot passes the release table, covering sterility, endotoxin, mycoplasma, viability, identity, purity, potency and karyotype. Failures are reported through B001-B006 instead of free text. Underneath these mechanics sit the biological relationships the standard encodes: the regeneration-rate model, the integration score threshold of 0.8, the vessel density range, and the match between factor half-life, scaffold degradation and tissue growth.
Three habits distinguish a sound implementation. It keeps raw counts next to computed percentages, configures thresholds per cell type, and links every clinical outcome back to a preparation identifier. A system with these habits can answer the questions a regulator, a clinician or a later researcher will ask about any given graft: what it was made from, how it was made, and what it did.
Passing the release gate shows that a single facility's records are internally consistent. The next chapter moves outward to the integration questions. It looks at how these preparation, QC and outcome records meet the wider ecosystem named in the standard (USP, ISO 14644, 21 CFR 1271, EU ATMP, ICH and GMP Annex 1) when they have to be exchanged, reconciled and defended across organisational boundaries.